integrin alpha7

RefSeq NM_001144996 (alpha-7 isoform 1 human); NM_008398 (alpha-7 mouse)

Also Known As:

CD49g antigen; ITGA7 protein, human; Itga7 protein, mouse; Itga7 protein, rat; alpha(7) integrin; alpha(7)-integrin; integrin alpha 7, mouse; integrin alpha 7, rat; integrin, alpha 7, human

Networked: 19 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Biological Factors: 2472
- Biomarkers: 240291
  - Differentiation Antigens: 2082
    - CD Antigens: 93
      - integrin alpha7: 19
- Antigens: 143924
  - Surface Antigens: 5813
    - Differentiation Antigens: 2082
      - CD Antigens: 93
        integrin alpha7: 19
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Cell Surface Receptors: 2125
      - Immunologic Receptors: 9
        Integrins: 14304
        Integrin alpha Chains: 91
        integrin alpha7: 19

Experts

1.	Luo, Jian-Hua: 3 articles (09/2010 - 06/2007)
2.	Nelson, Joel: 3 articles (09/2010 - 06/2007)
3.	Yu, Yan P: 3 articles (09/2010 - 06/2007)
4.	Kaufman, Stephen J: 3 articles (02/2008 - 07/2004)
5.	Michalopoulos, George K: 2 articles (06/2010 - 06/2007)
6.	Wu, Chuanyue: 2 articles (06/2010 - 06/2007)
7.	Chao, Jun-Tzu: 2 articles (04/2006 - 07/2004)
8.	Meininger, Gerald A: 2 articles (04/2006 - 07/2004)
9.	Ramos, Kenneth S: 2 articles (04/2006 - 07/2004)
10.	Wilson, Emily: 2 articles (04/2006 - 07/2004)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 06/06/2007 - "Integrin alpha7 mutations were associated with increased recurrence of human prostate cancer (nine recurrences among 13 patients with integrin alpha7 mutations versus one among eight without such mutations; odds ratio [OR] = 14, 95% CI = 1.15 to 782, P = .024) and hepatocellular carcinoma (five recurrences among eight patients with integrin alpha7 mutations versus one among 16 without such mutations, OR = 21, 95% CI = 1.6 to 1245; P = .007). " 06/06/2007 - "Focal or no integrin alpha7 expression in human prostate cancer and soft tissue leiomyosarcoma was associated with a reduction of metastasis-free survival (for example, for prostate cancer with focal or no expression, 5-year metastasis-free survival was 32%, 95% CI = 24.4% to 40.3%, and for prostate cancer with at least weak expression, it was 85%, 95% CI = 79% to 91%; P<.001). " 06/06/2007 - "Forced expression of normal integrin alpha7 in prostate cancer and leiomyosarcoma cell lines suppressed tumor growth and metastasis both in vitro and in vivo. " 06/06/2007 - "Integrin alpha7 mutations that generate truncations were found in specimens of 16 of 28 prostate cancers (57%, 95% confidence interval [CI] = 37% to 76%), five of 24 hepatocellular carcinomas (21%, 95% CI = 7% to 42%), five of six glioblastomas multiforme (83%, 95% CI = 36% to 99%), and one of four leiomyosarcomas (25%, 95% CI = 0.6% to 81%). " 06/06/2007 - "Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma."
2.	Liver Neoplasms (Liver Cancer) 06/06/2007 - "Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma." 09/01/2010 - "Previous studies identified down-regulation and/or mutations of integrin alpha7 (ITGA7) in prostate cancer, liver cancer, soft tissue leiomyosarcoma, and glioblastoma multiforme. "
3.	Leiomyosarcoma 06/06/2007 - "Focal or no integrin alpha7 expression in human prostate cancer and soft tissue leiomyosarcoma was associated with a reduction of metastasis-free survival (for example, for prostate cancer with focal or no expression, 5-year metastasis-free survival was 32%, 95% CI = 24.4% to 40.3%, and for prostate cancer with at least weak expression, it was 85%, 95% CI = 79% to 91%; P<.001). " 06/06/2007 - "Forced expression of normal integrin alpha7 in prostate cancer and leiomyosarcoma cell lines suppressed tumor growth and metastasis both in vitro and in vivo. " 06/06/2007 - "Integrin alpha7 mutations that generate truncations were found in specimens of 16 of 28 prostate cancers (57%, 95% confidence interval [CI] = 37% to 76%), five of 24 hepatocellular carcinomas (21%, 95% CI = 7% to 42%), five of six glioblastomas multiforme (83%, 95% CI = 36% to 99%), and one of four leiomyosarcomas (25%, 95% CI = 0.6% to 81%). " 06/06/2007 - "Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma." 06/06/2007 - "We evaluated the tumor suppressor activity of integrin alpha7 with colony formation, soft agar colony growth, and cell migration assays by forcing its expression in PC-3 and Du145 prostate cancer cells and SK-UT-1 leiomyosarcoma cells. "
4.	Glioblastoma (Glioblastoma Multiforme) 06/06/2007 - "Integrin alpha7 mutations that generate truncations were found in specimens of 16 of 28 prostate cancers (57%, 95% confidence interval [CI] = 37% to 76%), five of 24 hepatocellular carcinomas (21%, 95% CI = 7% to 42%), five of six glioblastomas multiforme (83%, 95% CI = 36% to 99%), and one of four leiomyosarcomas (25%, 95% CI = 0.6% to 81%). " 06/06/2007 - "Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma." 09/01/2010 - "Previous studies identified down-regulation and/or mutations of integrin alpha7 (ITGA7) in prostate cancer, liver cancer, soft tissue leiomyosarcoma, and glioblastoma multiforme. "
5.	Vascular System Injuries 07/01/2004 - "In the present study, the relationship between AAM-induced vascular injury and expression of the alpha(7)-integrin subunit was investigated. " 07/01/2004 - "These findings implicate for the first time the expression of alpha(7)-integrin during the response of VSMCs to vascular injury."

Related Drugs and Biologics

1.	integrin alpha7beta1
2.	Proteins (Proteins, Gene)
3.	Laminin (Merosin)
4.	Sarcoglycans (beta Sarcoglycan)
5.	Dystrophin
6.	Integrins
7.	Caspase 3 (Caspase-3)
8.	Myosin Heavy Chains (Myosin Heavy Chain)
9.	Complementary DNA (cDNA)
10.	Laminin Receptors